Performance & Impact
Hangaia te ā mua
Create the future
UniServices is the largest R&D company of its kind in Australasia. We’ve invested in over 75 companies and licensed more than 540 patent families. We’ve also delivered great community impact.
UniServices by the Numbers
8
new companies launched in 2023
35
patents licensed in 2024
$41m
– Fair value of the University of ߣߣƵInventors’ Fund at the end of 2023
28,592
Covid-19 vaccinator course completions through IMAC since 2021
36,659
– Clinical queries answered on IMAC’s 0800 IMMUNE phone line in 2023
6,755
people engaging with online courses through Whāraurau in 2023
5,366
people attending training and workshop courses through Whāraurau in 2023
Latest Highlights
Research Impact
Top in Australasia for active spin-outs
Ranked No. 1 in Australasia for active spin-outs, strengthening our role as a leading venture-creator. UniServices (and its parent University of Auckland) ranked #1 among 70+ Australian & New Zealand institutions in the number of active spin-out companies (47 from 2021-2023).
Major biopharma commercial deal with China
Landmark commercialisation deal with China, bringing a New Zealand-led cancer therapeutic to the global stage. In November 2024 UniServices announced the signing of a large patent acquisition deal for a novel oncology treatment (LX-132) with a Chinese biotech partner, described as “one of the largest biopharmaceutical commercialisation deals between New Zealand and China".
Global vaccine research partnership
In July 2024, UniServices and Kyushu University in Japan signed a Memorandum of Understanding to share vaccine research and data as part of the Global Vaccine Data Network, with King Luxon calling it “an excellent example of New Zealand demonstrating leadership of a global initiative in research and science.”
Enterprise value of NZ university spin-outs hits NZ$2.2 billion
and creating hundreds of skilled jobs. UniServices is proud to play a key role in the University of ߣߣƵinnovation ecosystem helping to deliver these outcomes. (August 2025)
Community Impact
Supporting Covid-19 vaccination
The (IMAC) plays a significant role in educating the country’s immunisation workforce. More than 5000 IMAC courses were completed by vaccinators across the motu in 2023. IMAC also advised healthcare staff through its 0800 phone line, answering more than 36,000 calls during the year. IMAC also provided expert advice to the government, and responded to continuous media queries.
Understanding whānau experiences
is the largest longitudinal study following the lives of more than 6,000 children, including some 1,200 tamariki Māori, since their pregnant mothers volunteered for the study in 2009. It offers evidence and insights into child and youth health and wellbeing in New Zealand for policymakers, researchers, community advocates, and other stakeholders.

Investment Impact

Better optical communications
Quantifi Photonics, a University of ߣߣƵspin-out, manufactures equipment for photonics testing and measurement in areas such as optical communications. It in Series C funding to accelerate the development of test solutions for datacom and telecom equipment manufacturers. It also , giving it research and manufacturing facilities in Thailand.
Diagnosing gut disorders
Alimetry is an ߣߣƵbased MedTech company that develops advanced wearable medical solutions that improve gastrointestinal care. Founded in 2019, based on a decade of groundbreaking science and engineering out of Waipapa Taumata Rau, the University of Auckland, Alimetry is striving to develop solutions that are more effective, easier on patients, and more efficient for healthcare providers. In 2022, Alimetry received FDA approval in the US for its flagship Gastric Alimetry device, a non-invasive tool to diagnose disorders of the upper gut, and has raised $16.3 million in Series A funding.
Check out our 2022 annual review
Learn what we achieved in advancing and investing in research and delivering services and projects with community impact.